You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

~ Buy the BREZTRI AEROSPHERE (budesonide; formoterol fumarate; glycopyrrolate) Drug Profile, 2024 PDF Report in the Report Store ~

BREZTRI AEROSPHERE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Breztri Aerosphere patents expire, and what generic alternatives are available?

Breztri Aerosphere is a drug marketed by Astrazeneca Ab and is included in one NDA. There are nine patents protecting this drug.

This drug has two hundred and nine patent family members in thirty-four countries.

The generic ingredient in BREZTRI AEROSPHERE is budesonide; formoterol fumarate; glycopyrrolate. There are twenty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the budesonide; formoterol fumarate; glycopyrrolate profile page.

DrugPatentWatch® Generic Entry Outlook for Breztri Aerosphere

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 28, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for BREZTRI AEROSPHERE?
  • What are the global sales for BREZTRI AEROSPHERE?
  • What is Average Wholesale Price for BREZTRI AEROSPHERE?
Summary for BREZTRI AEROSPHERE
International Patents:209
US Patents:9
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 1
DailyMed Link:BREZTRI AEROSPHERE at DailyMed
Drug patent expirations by year for BREZTRI AEROSPHERE
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for BREZTRI AEROSPHERE
Generic Entry Date for BREZTRI AEROSPHERE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
AEROSOL, METERED;INHALATION

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BREZTRI AEROSPHERE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jianxing HeN/A

See all BREZTRI AEROSPHERE clinical trials

US Patents and Regulatory Information for BREZTRI AEROSPHERE

BREZTRI AEROSPHERE is protected by nine US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of BREZTRI AEROSPHERE is ⤷  Subscribe.

This potential generic entry date is based on patent 8,703,806.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Ab BREZTRI AEROSPHERE budesonide; formoterol fumarate; glycopyrrolate AEROSOL, METERED;INHALATION 212122-001 Jul 23, 2020 RX Yes Yes 8,815,258 ⤷  Subscribe ⤷  Subscribe
Astrazeneca Ab BREZTRI AEROSPHERE budesonide; formoterol fumarate; glycopyrrolate AEROSOL, METERED;INHALATION 212122-001 Jul 23, 2020 RX Yes Yes 9,463,161 ⤷  Subscribe Y ⤷  Subscribe
Astrazeneca Ab BREZTRI AEROSPHERE budesonide; formoterol fumarate; glycopyrrolate AEROSOL, METERED;INHALATION 212122-001 Jul 23, 2020 RX Yes Yes 8,324,266 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for BREZTRI AEROSPHERE

When does loss-of-exclusivity occur for BREZTRI AEROSPHERE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 6621
Patent: COMPOSICIONES PARA EL SUMINISTRO DE ANTAGONISTAS MUSCARINICOS DE ACCION PROLONGADA Y AGONISTA DEL RECEPTOR ADRENERGICO B2 DE ACCION PROLONGADA. METODO DE TRATAMIENTO. SISTEMAS ASOCIADOS. INHALADOR DOSIFICADOR
Estimated Expiration: ⤷  Subscribe

Patent: 6806
Patent: COMPOSICIONES PARA EL SUMINISTRO DE AGENTES ACTIVOS MEDIANTE LAS VIAS RES-PIRATORIAS, Y METODOS Y SISTEMAS ASOCIADOS, COSUSPENSION, INHALADOR DOSIFI-CADOR
Estimated Expiration: ⤷  Subscribe

Patent: 6807
Patent: COMPOSICIONES METODOS Y SISTEMAS PARA EL SUMINISTRO DE DOS O MAS AGENTES ACTIVOS MEDIANTE LAS VIAS RESPIRATORIAS. METODO DE PREPARACION COMPOSICION
Estimated Expiration: ⤷  Subscribe

Patent: 1758
Patent: COMPOSICIÓN FARMACÉUTICA QUE PUEDE SUMINISTRARSE DESDE UN INHALADOR DOSIFICADOR
Estimated Expiration: ⤷  Subscribe

Patent: 2477
Patent: COMPOSICIONES PARA EL SUMINISTRO DE AGENTES ACTIVOS MEDIANTE LAS VÍAS RESPIRATORIAS, Y MÉTODOS Y SISTEMAS ASOCIADOS
Estimated Expiration: ⤷  Subscribe

Patent: 2478
Patent: COMPOSICIONES PARA EL SUMINISTRO PULMONAR DE ANTAGONISTAS MUSCARÍNICOS DE ACCIÓN PROLONGADA Y AGONISTAS DEL RECEPTOR ADRENÉRGICO b₂ DE ACCIÓN PROLONGADA, Y MÉTODOS Y SISTEMAS ASOCIADOS
Estimated Expiration: ⤷  Subscribe

Australia

Patent: 10253770
Patent: Compositions for respiratory delivery of active agents and associated methods and systems
Estimated Expiration: ⤷  Subscribe

Patent: 10253776
Patent: Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting B2 adrenergic receptor agonists and associated methods and systems
Estimated Expiration: ⤷  Subscribe

Patent: 10253950
Patent: Respiratory delivery of active agents
Estimated Expiration: ⤷  Subscribe

Patent: 15201037
Patent: Respiratory delivery of active agents
Estimated Expiration: ⤷  Subscribe

Patent: 17201709
Patent: Compositions, methods & systems for respiratory delivery of two or more active agents
Estimated Expiration: ⤷  Subscribe

Patent: 18282272
Patent: COMPOSITIONS, METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS
Estimated Expiration: ⤷  Subscribe

Patent: 20210160
Patent: COMPOSITIONS, METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS
Estimated Expiration: ⤷  Subscribe

Brazil

Patent: 1011220
Patent: composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada.
Estimated Expiration: ⤷  Subscribe

Patent: 1011229
Patent: co-suspensão, inalador de dose medida, e, métodos de preparação de um inalador de dose medida, de dispensação respiratória de um agente ativo a um paciente, e para tratar de um paciente.
Estimated Expiration: ⤷  Subscribe

Patent: 1011508
Patent: composição farmacêutica, métodos para tratar uma doença ou distúrbio pulmonar em um paciente ou população de pacientes, e para dispensação respiratória de um agente ativo a um paciente, e, inalador de dose medida.
Estimated Expiration: ⤷  Subscribe

Canada

Patent: 63936
Patent: COMPOSITIONS PERMETTANT L'ADMINISTRATION DE PRINCIPES ACTIFS PAR VOIE RESPIRATOIRE ET METHODES ET SYSTEMES ASSOCIES (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷  Subscribe

Patent: 63939
Patent: COMPOSITIONS PERMETTANT L'ADMINISTRATION PAR VOIE PULMONAIRE D'ANTAGONISTES, A ACTION PROLONGEE, DES RECEPTEURS MUSCARINIQUES ET D'AGONISTES, A ACTION PROLONGEE, DES RECEPTEURS ADRENERGIQUES B2 ET METHODES ET SYSTEMES ASSOCIES (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷  Subscribe

Patent: 63941
Patent: COMPOSITIONS, METHODES ET SYSTEMES PERMETTANT UNE ADMINISTRATION PAR VOIE RESPIRATOIRE DE DEUX PRINCIPES ACTIFS OU PLUS (COMPOSITIONS, METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS)
Estimated Expiration: ⤷  Subscribe

China

Patent: 2458364
Patent: Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
Estimated Expiration: ⤷  Subscribe

Patent: 2596176
Patent: Compositions for respiratory delivery of active agents and associated methods and systems
Estimated Expiration: ⤷  Subscribe

Patent: 2753152
Patent: Compositions, methods & systems for respiratory delivery of two or more active agents
Estimated Expiration: ⤷  Subscribe

Patent: 5193773
Patent: Respiratory delivery of active agents
Estimated Expiration: ⤷  Subscribe

Patent: 7412212
Patent: 经肺递送长效毒蕈碱拮抗剂及长效β2肾上腺素能受体激动剂的组合物及相关方法与系统 (Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta2 adrenergic receptor agonists and associated methods and systems)
Estimated Expiration: ⤷  Subscribe

Patent: 7669664
Patent: 经呼吸递送活性剂的组合物及相关方法和系统 (Compositions For Respiratory Delivery Of Active Agents And Associated Methods And Systems)
Estimated Expiration: ⤷  Subscribe

Croatia

Patent: 0161098
Estimated Expiration: ⤷  Subscribe

Patent: 0161101
Estimated Expiration: ⤷  Subscribe

Patent: 0161102
Estimated Expiration: ⤷  Subscribe

Patent: 0200166
Estimated Expiration: ⤷  Subscribe

Patent: 0200260
Estimated Expiration: ⤷  Subscribe

Patent: 0200298
Estimated Expiration: ⤷  Subscribe

Cyprus

Patent: 18030
Estimated Expiration: ⤷  Subscribe

Patent: 18034
Estimated Expiration: ⤷  Subscribe

Patent: 18040
Estimated Expiration: ⤷  Subscribe

Patent: 22732
Estimated Expiration: ⤷  Subscribe

Patent: 22749
Estimated Expiration: ⤷  Subscribe

Patent: 22807
Estimated Expiration: ⤷  Subscribe

Patent: 19031
Estimated Expiration: ⤷  Subscribe

Denmark

Patent: 35023
Estimated Expiration: ⤷  Subscribe

Patent: 35024
Estimated Expiration: ⤷  Subscribe

Patent: 35025
Estimated Expiration: ⤷  Subscribe

Patent: 06149
Estimated Expiration: ⤷  Subscribe

Patent: 11926
Estimated Expiration: ⤷  Subscribe

Patent: 11927
Estimated Expiration: ⤷  Subscribe

European Patent Office

Patent: 35023
Patent: COMPOSITIONS PERMETTANT L'ADMINISTRATION PAR VOIE PULMONAIRE D'ANTAGONISTES, À ACTION PROLONGÉE, DES RÉCEPTEURS MUSCARINIQUES ET D'AGONISTES, À ACTION PROLONGÉE, DES RÉCEPTEURS ADRÉNERGIQUES 2 ET MÉTHODES ET SYSTÈMES ASSOCIÉS (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING BETA 2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷  Subscribe

Patent: 35024
Patent: COMPOSITIONS PERMETTANT L'ADMINISTRATION DE PRINCIPES ACTIFS PAR VOIE RESPIRATOIRE ET MÉTHODES ET SYSTÈMES ASSOCIÉS (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷  Subscribe

Patent: 35025
Patent: ADMINISTRATION PAR VOIE RESPIRATOIRE DE PRINCIPES ACTIFS (RESPIRATORY DELIVERY OF ACTIVE AGENTS)
Estimated Expiration: ⤷  Subscribe

Patent: 06149
Patent: COMPOSITIONS POUR L'ADMINISTRATION PAR VOIE PULMONAIRE D'ANTAGONISTES MUSCARINIQUES ET AGONISTES DU RÉCEPTEUR ADRÉNERGIQUE BÉTA-2 À ACTION PROLONGÉE, PROCÉDÉS ET SYSTÈMES ASSOCIÉS (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING BETA-2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷  Subscribe

Patent: 11926
Patent: COMPOSITIONS, PROCÉDÉS ET SYSTÈMES POUR UNE ADMINISTRATION RESPIRATOIRE DE DEUX OU DE PLUSIEURS AGENTS ACTIFS (COMPOSITIONS, METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS)
Estimated Expiration: ⤷  Subscribe

Patent: 11927
Patent: COMPOSITIONS POUR ADMINISTRATION RESPIRATOIRE D'AGENTS ACTIFS ET MÉTHODES ET SYSTÈMES ASSOCIÉS (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷  Subscribe

Hong Kong

Patent: 69026
Patent: 用於經由肺部遞送長效蕈毒鹼拮抗劑及長效β 腎上腺素受體激動劑之組成物,及相關方法及系統 (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING BETA ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷  Subscribe

Patent: 69027
Patent: 用於經由呼吸道輸送活性劑的組成物以及相關方法與系統 (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷  Subscribe

Patent: 69307
Patent: 經由呼吸道遞送活性藥劑 (RESPIRATORY DELIVERY OF ACTIVE AGENTS)
Estimated Expiration: ⤷  Subscribe

Patent: 18867
Patent: 活性劑的呼吸遞送 (RESPIRATORY DELIVERY OF ACTIVE AGENTS)
Estimated Expiration: ⤷  Subscribe

Patent: 44669
Patent: 經肺遞送長效毒蕈堿拮抗劑及長效β2腎上腺素能受體激動劑的組合物及相關方法與系統 (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING β2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷  Subscribe

Patent: 47095
Patent: 經呼吸遞送活性劑的組合物及相關方法和系統 (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷  Subscribe

Hungary

Patent: 29532
Estimated Expiration: ⤷  Subscribe

Patent: 31229
Estimated Expiration: ⤷  Subscribe

Patent: 31283
Estimated Expiration: ⤷  Subscribe

Patent: 47803
Estimated Expiration: ⤷  Subscribe

Patent: 47823
Estimated Expiration: ⤷  Subscribe

Patent: 47834
Estimated Expiration: ⤷  Subscribe

Patent: 900031
Estimated Expiration: ⤷  Subscribe

Patent: 100018
Estimated Expiration: ⤷  Subscribe

Israel

Patent: 6466
Patent: תכשירים לנתינה למערכת הנשימה של גורמים פעילים ושיטות ומערכות קשורות (Compositions for respiratory delivery of active agents and associated methods and systems)
Estimated Expiration: ⤷  Subscribe

Patent: 6467
Patent: תרכובות פרמצבטיות למתן באמצעות משאף מינוני המכילות גליקופירולט או פורמוטרול ושמושן לטיפול במחלות נשימתיות (Pharmaceutical compositions deliverable from a metered dose inhaler comprising glycopyrrolate or formoterol and their use in treatment of pulmonary diseases)
Estimated Expiration: ⤷  Subscribe

Patent: 6468
Patent: תרכובות פרמצבטיות למתן באמצעות משאף מינוני המכילות גליקופירולט ופורמוטרול ושמושן לטיפול במחלות נשימתיות (Pharmaceutical compositions deliverable from a metered dose inhaler comprising glycopyrrolate and formoterol and their use in treatment of pulmonary diseases)
Estimated Expiration: ⤷  Subscribe

Japan

Patent: 23383
Estimated Expiration: ⤷  Subscribe

Patent: 73012
Estimated Expiration: ⤷  Subscribe

Patent: 73013
Estimated Expiration: ⤷  Subscribe

Patent: 69639
Estimated Expiration: ⤷  Subscribe

Patent: 89356
Estimated Expiration: ⤷  Subscribe

Patent: 48645
Estimated Expiration: ⤷  Subscribe

Patent: 92124
Estimated Expiration: ⤷  Subscribe

Patent: 76734
Estimated Expiration: ⤷  Subscribe

Patent: 12528199
Estimated Expiration: ⤷  Subscribe

Patent: 12528200
Estimated Expiration: ⤷  Subscribe

Patent: 12528792
Estimated Expiration: ⤷  Subscribe

Patent: 15187108
Patent: 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷  Subscribe

Patent: 15199735
Patent: 2つ以上の活性剤を呼吸器送達するための組成物、方法および系 (COMPOSITION, METHOD AND SYSTEM FOR DELIVERING TWO OR MORE ACTIVATORS TO RESPIRATORY ORGAN)
Estimated Expiration: ⤷  Subscribe

Patent: 16041713
Patent: 長時間作用性のムスカリン拮抗剤および長時間作用性のΒ2アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING BETA2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷  Subscribe

Patent: 17222706
Patent: 2つ以上の活性剤を呼吸器送達するための組成物、方法および系 (COMPOSITIONS, METHODS AND SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS)
Estimated Expiration: ⤷  Subscribe

Patent: 18008942
Patent: 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 (COMPOSITION FOR RESPIRATORY DELIVERY OF ACTIVE AGENT, AND RELATED METHOD AND SYSTEM)
Estimated Expiration: ⤷  Subscribe

Patent: 18048150
Patent: 長時間作用性のムスカリン拮抗剤および長時間作用性のΒ2アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS, AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷  Subscribe

Patent: 19108369
Patent: 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷  Subscribe

Lithuania

Patent: 435024
Estimated Expiration: ⤷  Subscribe

Patent: 435025
Estimated Expiration: ⤷  Subscribe

Patent: 2019014
Estimated Expiration: ⤷  Subscribe

Patent: 2021511
Estimated Expiration: ⤷  Subscribe

Patent: 35023
Estimated Expiration: ⤷  Subscribe

Patent: 35024
Estimated Expiration: ⤷  Subscribe

Patent: 35025
Estimated Expiration: ⤷  Subscribe

Patent: 06149
Estimated Expiration: ⤷  Subscribe

Patent: 11926
Estimated Expiration: ⤷  Subscribe

Patent: 11927
Estimated Expiration: ⤷  Subscribe

Luxembourg

Patent: 0124
Estimated Expiration: ⤷  Subscribe

Patent: 0208
Estimated Expiration: ⤷  Subscribe

Mexico

Patent: 7126
Patent: ADMINISTRACION RESPIRATORIA DE AGENTES ACTIVOS. (RESPIRATORY DELIVERY OF ACTIVE AGENTS.)
Estimated Expiration: ⤷  Subscribe

Patent: 0163
Patent: COMPOSICIONES PARA SUMINISTRO RESPIRATORIO DE AGENTES ACTIVOS Y METODOS Y SISTEMAS ASOCIADOS. (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS.)
Estimated Expiration: ⤷  Subscribe

Patent: 0164
Patent: COMPOSICIONES PARA SUMINISTRO PULMONAR DE ANTAGONISTAS MUSCARÍNICOS DE ACCIÓN PROLONGADA Y AGONISTAS DE RECEPTOR B2 ADRENÉRGICO DE ACCIÓN PROLONGADA Y MÉTODOS Y SISTEMAS ASOCIADOS. (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS.)
Estimated Expiration: ⤷  Subscribe

Patent: 11012684
Patent: COMPOSICIONES PARA SUMINISTRO RESPIRATORIO DE AGENTES ACTIVOS Y METODOS Y SISTEMAS ASOCIADOS. (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS.)
Estimated Expiration: ⤷  Subscribe

Patent: 11012685
Patent: COMPOSICIONES PARA SUMINISTRO PULMONAR DE ANTAGONISTAS MUSCARINICOS DE ACCION PROLONGADA Y AGONISTAS DE RECEPTOR B2 ADRENERGICO DE ACCION PROLONGADA Y METODOS Y SISTEMAS ASOCIADOS. (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS.)
Estimated Expiration: ⤷  Subscribe

Patent: 11012783
Patent: ADMINISTRACION RESPIRATORIA DE AGENTES ACTIVOS. (RESPIRATORY DELIVERY OF ACTIVE AGENTS.)
Estimated Expiration: ⤷  Subscribe

Patent: 20004077
Patent: COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE LA COMBINACIÓN DE ALBUTEROL Y BUDESÓNIDA, ADAPTADA PARA EL SUMINISTRO RESPIRATORIO MEDIANTE UN INHALADOR DE DOSIS MEDIDA Y EL USO DE LAS MISMAS PARA EL TRATAMIENTO DE TRASTORNOS PULMONARES. (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS.)
Estimated Expiration: ⤷  Subscribe

Montenegro

Patent: 631
Patent: SASTAVI ZA ISPORUKU AKTIVNIH AGENASA U DISAJNE PUTEVE I POVEZANI POSTUPCI I SISTEMI (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷  Subscribe

Netherlands

Patent: 0995
Estimated Expiration: ⤷  Subscribe

Norway

Patent: 19026
Estimated Expiration: ⤷  Subscribe

Patent: 21019
Estimated Expiration: ⤷  Subscribe

Philippines

Patent: 017500778
Patent: COMPOSITIONS, METHODS and SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS
Estimated Expiration: ⤷  Subscribe

Poland

Patent: 35023
Estimated Expiration: ⤷  Subscribe

Patent: 35024
Estimated Expiration: ⤷  Subscribe

Patent: 35025
Estimated Expiration: ⤷  Subscribe

Patent: 06149
Estimated Expiration: ⤷  Subscribe

Patent: 11926
Estimated Expiration: ⤷  Subscribe

Patent: 11927
Estimated Expiration: ⤷  Subscribe

Portugal

Patent: 35023
Estimated Expiration: ⤷  Subscribe

Patent: 35024
Estimated Expiration: ⤷  Subscribe

Patent: 35025
Estimated Expiration: ⤷  Subscribe

Patent: 06149
Estimated Expiration: ⤷  Subscribe

Patent: 11926
Estimated Expiration: ⤷  Subscribe

Patent: 11927
Estimated Expiration: ⤷  Subscribe

Russian Federation

Patent: 80315
Patent: КОМПОЗИЦИИ ДЛЯ РЕСПИРАТОРНОЙ ДОСТАВКИ АКТИВНЫХ ВЕЩЕСТВ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE SUBSTANCES AND METHODS AND SYSTEMS CONNECTED THEREWITH)
Estimated Expiration: ⤷  Subscribe

Patent: 86297
Patent: КОМПОЗИЦИИ, СПОСОБЫ И СИСТЕМЫ ДЛЯ РЕСПИРАТОРНОЙ ДОСТАВКИ ДВУХ ИЛИ БОЛЕЕ АКТИВНЫХ АГЕНТОВ (COMPOSITIONS, METHODS AND SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS)
Estimated Expiration: ⤷  Subscribe

Patent: 13404
Patent: КОМПОЗИЦИИ ДЛЯ ЛЕГОЧНОЙ ДОСТАВКИ АНТАГОНИСТОВ МУСКАРИНОВЫХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И АГОНИСТОВ В2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC RECEPTOR ANTAGONISTS AND LONG-ACTING B2-ADRENERGIC RECEPTOR AGONISTS AND METHODS AND SYSTEMS ASSOCIATED THEREWITH)
Estimated Expiration: ⤷  Subscribe

Patent: 51771
Patent: КОМПОЗИЦИИ ДЛЯ РЕСПИРАТОРНОЙ ДОСТАВКИ АКТИВНЫХ ВЕЩЕСТВ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE SUBSTANCES AND METHODS AND SYSTEMS ASSOCIATED THEREWITH)
Estimated Expiration: ⤷  Subscribe

Patent: 11152960
Patent: КОМПОЗИЦИИ ДЛЯ ЛЕГОЧНОЙ ДОСТАВКИ АНТАГОНИСТОВ МУСКАРИНОВЫХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И АГОНИСТОВ β-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ
Estimated Expiration: ⤷  Subscribe

Patent: 11154083
Patent: КОМПОЗИЦИИ ДЛЯ РЕСПИРАТОРНОЙ ДОСТАВКИ АКТИВНЫХ ВЕЩЕСТВ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ
Estimated Expiration: ⤷  Subscribe

Patent: 11154148
Patent: КОМПОЗИЦИИ, СПОСОБЫ И СИСТЕМЫ ДЛЯ РЕСПИРАТОРНОЙ ДОСТАВКИ ДВУХ ИЛИ БОЛЕЕ АКТИВНЫХ АГЕНТОВ
Estimated Expiration: ⤷  Subscribe

Patent: 15151358
Patent: КОМПОЗИЦИИ ДЛЯ ЛЕГОЧНОЙ ДОСТАВКИ АНТАГОНИСТОВ МУСКАРИНОВЫХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И АГОНИСТОВ В2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ
Estimated Expiration: ⤷  Subscribe

Patent: 16107464
Patent: КОМПОЗИЦИИ ДЛЯ РЕСПИРАТОРНОЙ ДОСТАВКИ АКТИВНЫХ ВЕЩЕСТВ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ
Estimated Expiration: ⤷  Subscribe

Patent: 16117972
Patent: КОМПОЗИЦИИ, СПОСОБЫ И СИСТЕМЫ ДЛЯ РЕСПИРАТОРНОЙ ДОСТАВКИ ДВУХ ИЛИ БОЛЕЕ АКТИВНЫХ АГЕНТОВ
Estimated Expiration: ⤷  Subscribe

Patent: 20102859
Patent: КОМПОЗИЦИИ ДЛЯ ЛЕГОЧНОЙ ДОСТАВКИ АНТАГОНИСТОВ МУСКАРИНОВЫХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И АГОНИСТОВ B2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ
Estimated Expiration: ⤷  Subscribe

San Marino

Patent: 01600326
Patent: DISTRIBUZIONE RESPIRATORIA DI PRINCIPI ATTIVI
Estimated Expiration: ⤷  Subscribe

Patent: 01600327
Patent: COMPOSIZIONI PER IL RILASCIO POLMONARE DI ANTAGONISTI MUSCARINICI AD AZIONE PROLUNGATA E DI AGONISTI DEL RECETTORE ADRENERGICO BETA 2 AD AZIONE PROLUNGATA E METODI E SISTEMI ASSOCIATI
Estimated Expiration: ⤷  Subscribe

Patent: 01600329
Patent: COMPOSIZIONI PER LA DISTRIBUZIONE RESPIRATORIA DI PRINCIPI ATTIVI E METODI E SISTEMI ASSOCIATI
Estimated Expiration: ⤷  Subscribe

Slovenia

Patent: 35023
Estimated Expiration: ⤷  Subscribe

Patent: 35024
Estimated Expiration: ⤷  Subscribe

Patent: 35025
Estimated Expiration: ⤷  Subscribe

Patent: 06149
Estimated Expiration: ⤷  Subscribe

Patent: 11926
Estimated Expiration: ⤷  Subscribe

Patent: 11927
Estimated Expiration: ⤷  Subscribe

South Africa

Patent: 1108275
Patent: RESPIRATORY DELIVERY OF ACTIVE AGENTS
Estimated Expiration: ⤷  Subscribe

Patent: 1208100
Patent: COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS
Estimated Expiration: ⤷  Subscribe

Patent: 1208101
Patent: COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS
Estimated Expiration: ⤷  Subscribe

Patent: 1208102
Patent: RESPIRATORY DELIVERY OF ACTIVE AGENTS
Estimated Expiration: ⤷  Subscribe

South Korea

Patent: 1748892
Estimated Expiration: ⤷  Subscribe

Patent: 1926060
Estimated Expiration: ⤷  Subscribe

Patent: 1976107
Estimated Expiration: ⤷  Subscribe

Patent: 120015334
Patent: COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS
Estimated Expiration: ⤷  Subscribe

Patent: 120026075
Patent: RESPIRATORY DELIVERY OF ACTIVE AGENTS
Estimated Expiration: ⤷  Subscribe

Patent: 120034631
Patent: COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS
Estimated Expiration: ⤷  Subscribe

Patent: 170070274
Patent: 지속형 무스카린 안타고니스트 및 지속형 B₂아드레날린 수용체 아고니스트의 폐 전달용 조성물, 및 연관된 방법 및 시스템 (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷  Subscribe

Patent: 170104003
Patent: 활성제의 호흡기 전달용 조성물, 및 연관된 방법 및 시스템 (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷  Subscribe

Patent: 180130602
Patent: 활성제의 호흡기 전달용 조성물, 및 연관된 방법 및 시스템 (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷  Subscribe

Patent: 190049943
Patent: 활성제의 호흡기 전달 (RESPIRATORY DELIVERY OF ACTIVE AGENTS)
Estimated Expiration: ⤷  Subscribe

Spain

Patent: 89135
Estimated Expiration: ⤷  Subscribe

Patent: 92536
Estimated Expiration: ⤷  Subscribe

Patent: 93429
Estimated Expiration: ⤷  Subscribe

Patent: 72253
Estimated Expiration: ⤷  Subscribe

Patent: 74367
Estimated Expiration: ⤷  Subscribe

Patent: 74391
Estimated Expiration: ⤷  Subscribe

Taiwan

Patent: 39979
Estimated Expiration: ⤷  Subscribe

Patent: 46094
Estimated Expiration: ⤷  Subscribe

Patent: 32926
Estimated Expiration: ⤷  Subscribe

Patent: 33898
Estimated Expiration: ⤷  Subscribe

Patent: 46980
Estimated Expiration: ⤷  Subscribe

Patent: 95723
Estimated Expiration: ⤷  Subscribe

Patent: 07700
Estimated Expiration: ⤷  Subscribe

Patent: 17511
Estimated Expiration: ⤷  Subscribe

Patent: 92140
Estimated Expiration: ⤷  Subscribe

Patent: 1109049
Patent: Compositions for respiratory delivery of active agents and associated methods and systems
Estimated Expiration: ⤷  Subscribe

Patent: 1109050
Patent: Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting &bgr;2 adrenergic receptor agonists and associated methods and systems
Estimated Expiration: ⤷  Subscribe

Patent: 1109051
Patent: Compositions, methods and systems for respiratory delivery of two or more active agents
Estimated Expiration: ⤷  Subscribe

Patent: 1642836
Patent: Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting [beta]2 adrenergic receptor agonists and associated methods and systems
Estimated Expiration: ⤷  Subscribe

Patent: 1700123
Patent: Compositions for respiratory delivery of active agents and associated methods and systems
Estimated Expiration: ⤷  Subscribe

Patent: 1808372
Patent: Compositions, methods and systems for respiratory delivery of two or more active agents
Estimated Expiration: ⤷  Subscribe

Patent: 1919730
Patent: Compositions for respiratory delivery of active agents and associated methods and systems
Estimated Expiration: ⤷  Subscribe

Patent: 1936174
Patent: Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting [beta]2 adrenergic receptor agonists and associated methods and systems
Estimated Expiration: ⤷  Subscribe

Patent: 2114642
Patent: Compositions, methods and systems for respiratory delivery of two or more active agents
Estimated Expiration: ⤷  Subscribe

Ukraine

Patent: 9529
Patent: КОМПОЗИЦІЇ ДЛЯ РЕСПІРАТОРНОЇ ДОСТАВКИ АКТИВНИХ АГЕНТІВ ТА ПОВ'ЯЗАНІ СПОСОБИ І СИСТЕМИ
Estimated Expiration: ⤷  Subscribe

Patent: 9530
Patent: КОМПОЗИЦІЇ, СПОСОБИ ТА СИСТЕМИ ДЛЯ ДОСТАВКИ РЕСПІРАТОРНИМ ШЛЯХОМ ДВОХ ЧИ БІЛЬШЕ АКТИВНИХ АГЕНТІВ
Estimated Expiration: ⤷  Subscribe

Patent: 9531
Patent: КОМПОЗИЦІЇ ДЛЯ ЛЕГЕНЕВОЇ ДОСТАВКИ МУСКАРИНОВИХ АНТАГОНІСТІВ ТРИВАЛОЇ ДІЇ ТА АГОНІСТІВ АДРЕНЕРГІЧНИХ РЕЦЕПТОРІВ B2 ТРИВАЛОЇ ДІЇ ТА ПОВ'ЯЗАНІ СПОСОБИ І СИСТЕМИ
Estimated Expiration: ⤷  Subscribe

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BREZTRI AEROSPHERE around the world.

Country Patent Number Title Estimated Expiration
South Korea 20120015334 COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS ⤷  Subscribe
Ukraine 109529 КОМПОЗИЦІЇ ДЛЯ РЕСПІРАТОРНОЇ ДОСТАВКИ АКТИВНИХ АГЕНТІВ ТА ПОВ'ЯЗАНІ СПОСОБИ І СИСТЕМИ ⤷  Subscribe
South Korea 20120015334 ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for BREZTRI AEROSPHERE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2435024 122021000026 Germany ⤷  Subscribe PRODUCT NAME: GLYCOPYRROLAT MIT FORMOTEROL MIT BUDESONID, ODER SALZE, ESTER, SOLVATE, ENANTIOMERE UND MISCHUNGEN VON ENANTIOMEREN DERSELBEN; REGISTRATION NO/DATE: EU/1/20/1498 20201209
2435024 LUC00208 Luxembourg ⤷  Subscribe PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), DE GLYCOPYRRONIUM (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE BUDESONIDE (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1468 20201210
2435025 122019000068 Germany ⤷  Subscribe PRODUCT NAME: KOMBINATION VON GLYCOPYRROLAT, EINSCHLIESSLICH BELIEBIGER PHARMAZEUTISCH VERTRAEGLICHER SALZE, ESTER, ENANTIOMERE, ODER ANDERER DERIVATE DAVON, UND FORMOTEROL, EINSCHLIESSLICH BELIEBIGER PHARMAZEUTISCH VERTRAEGLICHER SALZE, ESTER, ENANTIOMERE, ODER ANDERER DERIVATE DAVON; REGISTRATION NO/DATE: EU/1/18/1339 20181218
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

BREZTRI AEROSPHERE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Breztri Aerosphere

Introduction

Breztri Aerosphere, a triple-combination therapy inhaler developed by AstraZeneca, has been making significant waves in the chronic obstructive pulmonary disease (COPD) market. Here, we delve into the market dynamics and financial trajectory of this drug, highlighting its clinical successes, market positioning, and financial implications.

Clinical Successes and Trials

Breztri Aerosphere has demonstrated impressive clinical results, particularly in the Phase III ETHOS trial. This trial showed that Breztri Aerosphere reduced exacerbations in patients with moderate to severe COPD by 24% compared to dual-drug combination therapies over 52 weeks[1][4].

The ETHOS trial built upon the promising data from the KRONOS trial, which led to Breztri Aerosphere's first approval by the Japanese Ministry of Health, Labor and Welfare in June 2019. These positive results have set the stage for anticipated rapid approvals in the EU and US, further solidifying AstraZeneca's position in the COPD market[1].

Market Positioning

AstraZeneca is entering a market where GlaxoSmithKline's (GSK) Trelegy Ellipta has already established a presence. However, AstraZeneca's extensive experience and the familiarity of physicians with its predecessor, Symbicort (budesonide/formoterol fumarate), are expected to drive significant uptake of Breztri Aerosphere. Symbicort has consistently outperformed GSK's Relvar Ellipta in sales, indicating a strong potential for Breztri in the triple-combination therapy segment[1].

Key opinion leaders have indicated a preference for switching patients from separate ICS/LABA and LAMA devices to a single ICS/LABA/LAMA device to improve adherence. This trend is expected to boost Breztri Aerosphere's market access strategy[1].

Financial Trajectory

Revenue Projections

Breztri Aerosphere is anticipated to achieve blockbuster sales levels over the next decade. The combination of promising trial data, variable dosing, and the advanced Aerosphere Delivery Technology is expected to drive swift uptake and significant revenue growth. AstraZeneca's extensive marketing experience will also play a crucial role in catapulting sales and overcoming the late market entry[1].

Financial Performance of AstraZeneca

In 2022, AstraZeneca reported a total revenue increase of 25% to $11.207 billion, with a strong pipeline progress and multiple approvals in major markets. The company expects another year of double-digit revenue growth in 2023, excluding COVID-19 medicines. This growth trajectory sets a positive backdrop for the financial performance of Breztri Aerosphere[2].

Regional Sales and Market Impact

Breztri Aerosphere has already been approved in Japan and China. While the FDA rejection in the past gave GSK's Trelegy Ellipta a head start in the US market, the recent clinical trial successes are expected to help Breztri Aerosphere gain ground. The drug's performance in reducing exacerbations and its approval in key markets will be pivotal in its financial success[4].

Cost and Accessibility

The cost of Breztri Aerosphere can vary based on insurance plans and other factors. As a brand-name drug, it is currently more expensive due to the extensive research and development costs involved. However, once the patent expires, the potential for generic versions could lead to lower costs for patients[5].

Competitive Landscape

AstraZeneca and GSK have been competitors in the respiratory market for some time. While Trelegy Ellipta has an established presence, Breztri Aerosphere's clinical data and AstraZeneca's marketing prowess are expected to make it a strong contender. The competition between these two companies will continue to shape the COPD treatment landscape[4].

Future Outlook

AstraZeneca's commitment to innovation in respiratory diseases is evident from its ongoing research and development efforts. The company's collaboration with Amgen on other respiratory and immune-mediated diseases further strengthens its pipeline and portfolio. This broad pipeline and portfolio are crucial for sustaining long-term growth and market dominance[3].

Key Takeaways

  • Clinical Success: Breztri Aerosphere has shown significant reductions in COPD exacerbations in clinical trials.
  • Market Positioning: AstraZeneca's experience and physician familiarity with Symbicort will drive uptake.
  • Financial Trajectory: Anticipated blockbuster sales levels over the next decade.
  • Competitive Landscape: Strong competition with GSK's Trelegy Ellipta, but AstraZeneca's marketing and clinical data are advantageous.
  • Cost and Accessibility: Currently expensive as a brand-name drug, but potential for lower costs with generic versions in the future.

FAQs

  1. What are the active ingredients in Breztri Aerosphere?

    • The active ingredients in Breztri Aerosphere are budesonide, glycopyrrolate, and formoterol fumarate[5].
  2. What were the key findings of the ETHOS trial for Breztri Aerosphere?

    • The ETHOS trial showed a 24% reduction in exacerbations over 52 weeks compared to dual-drug combination therapies[1][4].
  3. How does Breztri Aerosphere compare to GSK's Trelegy Ellipta?

    • While Trelegy Ellipta has an established presence, Breztri Aerosphere's clinical data and AstraZeneca's marketing experience are expected to make it a strong competitor[4].
  4. What is the current market approval status of Breztri Aerosphere?

    • Breztri Aerosphere is approved in Japan and China, with anticipated approvals in the EU and US based on recent clinical trial successes[1][4].
  5. How can patients reduce the cost of Breztri Aerosphere?

    • Patients can lower the cost through insurance plans, coupons, and potentially generic versions once the patent expires[5].

Sources

  1. Clinical Trials Arena: AstraZeneca's Breztri Aerosphere is a late-stage blockbuster.
  2. AstraZeneca: Full year and Q4 2022 results.
  3. AstraZeneca: AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024.
  4. FiercePharma: AstraZeneca touts triplet inhaler Breztri's COPD win ahead of key FDA decision.
  5. Medical News Today: Breztri Aerosphere cost 2024: Coupons and more.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.